Proteon Therapeutics, a biotech developing a recombinant protein for patients undergoing surgery for kidney failure, announced terms for its IPO on Tuesday. The Waltham, MA-based company plans to raise $61 million by offering 4.7 million shares at a price range...read more
Ardelyx, which is developing therapies to control the progression of late-stage kidney disease, raised $60 million by offering 4.3 million shares (vs. 3.6 million originally planned) at $14, the midpoint of its $13 to $15 range. Ardelyx will list on the NASDAQ...read more
Ardelyx, a biotech developing small molecule treatments for kidney and gastrointestinal diseases, announced terms for its IPO on Monday. The Fremont, CA-based company plans to raise $50 million by offering 3.6 million shares at a price range of $13 to $15. At...read more
Kidney failure biotech Proteon Therapeutics sets terms for $61 million IPO
Proteon Therapeutics, a biotech developing a recombinant protein for patients undergoing surgery for kidney failure, announced terms for its IPO on Tuesday. The Waltham, MA-based company plans to raise $61 million by offering 4.7 million shares at a price range...read more
Ardelyx prices upsized IPO at $14 midpoint
Ardelyx, which is developing therapies to control the progression of late-stage kidney disease, raised $60 million by offering 4.3 million shares (vs. 3.6 million originally planned) at $14, the midpoint of its $13 to $15 range. Ardelyx will list on the NASDAQ...read more
12 US IPOs planned for the week of Jun 16
The following IPOs are expected to price this week: Ardelyx (ARDX), a biotech developing small molecule treatments for kidney and gastrointestinal diseases, plans to...read more
Small molecule biotech Ardelyx sets terms for $50 million IPO
Ardelyx, a biotech developing small molecule treatments for kidney and gastrointestinal diseases, announced terms for its IPO on Monday. The Fremont, CA-based company plans to raise $50 million by offering 3.6 million shares at a price range of $13 to $15. At...read more